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Background: Topotecan is an active agent for relapsed or recurrent 
SCLC. Combination chemotherapy of topotecan and carboplatin for re-
lapsed SCLC has not been fully evaluated. To determine the maximum-
tolerated dose (MTD), a phase I study was conducted. 
Method: Patients with measurable disease and one prior chemotherapy 
regimen excluding topotecan were enrolled in this study. Topotecan 
was administered through days 1 to 5, whereas carboplatin was admin-
istered on day 5. Courses were repeated every 3 weeks. The starting 
doses of topotecan and carboplatin were 0.50 mg/m2/day and AUC=5, 
respectively. The dose levels examined are shown in the table below. 
Results: A total of 32 patients with relapsed SCLC have been enrolled. 
Patient characteristics are as follows: median age, 64 yrs (range 43-74); 
male/female, 23/9; ECOG PS 0/1, 15/17 patients. Dose-limiting toxici-
ties (DLTs) were observed in 1 patient at dose level 1 (infection), level 
3 (diarrhea), and level 5 (thrombocytopenia), respectively. Three of 6 
patients have experienced DLTs at dose level 6 (thrombocytopenia). 
MTD of topotecan and carboplatin were determined to be 0.85 mg/m2 
and AUC=5, respectively. Five of 29 (17%) assessable patients have 
responded to treatment with a partial response (PR), and 13 (45%) 
patients have had stable disease (SD) at best response. 
Conclusions: The recommended doses are 0.75mg/m2 of topotecan and 
AUC=5 of carboplatin. The combination of topotecan and carboplatin 
shows an acceptable activity and toxicity proﬁle in relapsed SCLC 
patients. Further study in the phase III setting is warranted.
Level (no. of pts.)
Topotecan (mg/m2)/ 
Carboplatin (AUC)
Cycle 1 DLTs Responses (PR/SD)
1 (n=6) 0.50/5 1 0/2
2 (n=3) 0.60/5 0 0/1
3 (n=8) 0.65/5 1 2/2
4 (n=3) 0.70/5 0 0/3
5 (n=6) 0.75/5 1 0/4
6 (n=6) 0.85/5 3 3/1
Total (n=32) 6 5/13
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The impact of shortened vitamin supplementation lead-in time 
before pemetrexed (P) in patients with relapsed small-cell lung 
cancer (SCLC)
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Background: Clinical studies of P have shown less overall toxicity and 
reductions in Grades 3/4 hematologic and nonhematologic toxicities 
when pts are pretreated with folic acid and Vitamin B
12
. Current recom-
mendations are to give folic acid 350 µg to 1000 µg by mouth for at 
least 5 of 7 days prior to the 1st dose of P, and 1 injection of Vitamin 
B
12
 1000 µg during the week preceding the 1st P dose. Treatment delay 
to allow this supplementation may be clinically undesirable, particular-
ly in pts with aggressive malignancies. A trial evaluating single-agent P 
for the treatment of relapsed SCLC gave us opportunity to observe the 
effects of a shortened lead-in time for vitamin supplementation.
Methods: We reviewed data from a US trial designed to assess the 
safety and efﬁcacy of single-agent P in chemosensitive and chemore-
fractory relapsed SCLC pts. Eligible pts had limited or extensive-stage 
SCLC, PS 0 to 2, and 1 prior chemo regimen. Pts received P doses of 
500 mg/m2 or 900 mg/m2 q 21 d. The protocol required the administra-
tion of folic acid for at least 5 of 7 days prior to the 1st P dose, and 
Vitamin B
12
 administration on Day 1, Cycle 1, or up to 14 days prior to 
